CN1976704B - 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途 - Google Patents

取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途 Download PDF

Info

Publication number
CN1976704B
CN1976704B CN2005800170162A CN200580017016A CN1976704B CN 1976704 B CN1976704 B CN 1976704B CN 2005800170162 A CN2005800170162 A CN 2005800170162A CN 200580017016 A CN200580017016 A CN 200580017016A CN 1976704 B CN1976704 B CN 1976704B
Authority
CN
China
Prior art keywords
mycobacterium
phenyl
quinoline
strain
naphthyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800170162A
Other languages
English (en)
Chinese (zh)
Other versions
CN1976704A (zh
Inventor
K·J·L·M·安德里斯
J·F·E·范格斯特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34929150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1976704(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN1976704A publication Critical patent/CN1976704A/zh
Application granted granted Critical
Publication of CN1976704B publication Critical patent/CN1976704B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2005800170162A 2004-05-28 2005-05-24 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途 Expired - Fee Related CN1976704B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04102402 2004-05-28
EP04102402.7 2004-05-28
PCT/EP2005/052371 WO2005117875A1 (en) 2004-05-28 2005-05-24 Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012103943126A Division CN102908347A (zh) 2004-05-28 2005-05-24 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途

Publications (2)

Publication Number Publication Date
CN1976704A CN1976704A (zh) 2007-06-06
CN1976704B true CN1976704B (zh) 2012-12-05

Family

ID=34929150

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2005800170162A Expired - Fee Related CN1976704B (zh) 2004-05-28 2005-05-24 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途
CN2012103943126A Pending CN102908347A (zh) 2004-05-28 2005-05-24 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012103943126A Pending CN102908347A (zh) 2004-05-28 2005-05-24 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途

Country Status (34)

Country Link
US (2) US20070249667A1 (enExample)
EP (1) EP1753427B1 (enExample)
JP (2) JP5081617B2 (enExample)
KR (2) KR20130024969A (enExample)
CN (2) CN1976704B (enExample)
AP (1) AP2037A (enExample)
AR (1) AR049127A1 (enExample)
AT (1) ATE390925T1 (enExample)
AU (1) AU2005249231B2 (enExample)
BR (1) BRPI0510414B1 (enExample)
CA (1) CA2566544C (enExample)
CL (1) CL2009001980A1 (enExample)
CY (1) CY1110388T1 (enExample)
DE (1) DE602005005810T2 (enExample)
DK (1) DK1753427T3 (enExample)
EA (1) EA010651B1 (enExample)
ES (1) ES2306146T3 (enExample)
HR (1) HRP20080307T3 (enExample)
IL (1) IL179630A (enExample)
JO (1) JO2524B1 (enExample)
ME (1) ME01105B (enExample)
MX (1) MXPA06013888A (enExample)
MY (1) MY140611A (enExample)
NO (1) NO338624B1 (enExample)
NZ (1) NZ550840A (enExample)
PA (1) PA8635201A1 (enExample)
PL (1) PL1753427T3 (enExample)
PT (1) PT1753427E (enExample)
RS (1) RS50585B (enExample)
SI (1) SI1753427T1 (enExample)
TW (1) TWI363625B (enExample)
UA (1) UA90267C2 (enExample)
WO (1) WO2005117875A1 (enExample)
ZA (1) ZA200609899B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102908347A (zh) * 2004-05-28 2013-02-06 詹森药业有限公司 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途
CN105330595A (zh) * 2014-07-14 2016-02-17 南京明德新药研发股份有限公司 吡啶衍生物及其作为抗分支杆菌的应用

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101301573B1 (ko) * 2004-12-24 2013-09-04 얀센 파마슈티카 엔.브이. 잠재성 튜버큐로시스의 치료법
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained
JP5349730B2 (ja) * 2005-06-09 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としてのキノリン誘導体
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
CA2612614C (en) * 2005-06-28 2017-07-25 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
EP1917245A1 (de) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2685B1 (en) 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
AU2010292148A1 (en) * 2009-09-11 2012-04-12 Vertex Pharmaceuticals Incorporated Compositions of N-benzyl-3-(4-chlorophenyl)-2- [methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl) acetyl]amino]-N- [3-(4-pyridyl)-1-[2-[4-pyridyl)ethy]propyl]propanamide and uses thereof
CN102249935B (zh) * 2010-05-17 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 芳香2-丁醇类化合物及其医药用途
US9133167B2 (en) 2012-04-27 2015-09-15 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
KR102110366B1 (ko) 2012-04-27 2020-05-14 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체
CA2954872C (en) * 2014-07-14 2019-08-13 Cisen Pharmaceutical Co., Ltd. Pyridine derivatives and anti-mycobacterial use thereof
CN114129526A (zh) 2015-01-27 2022-03-04 詹森药业有限公司 可分散组合物
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
US10196360B2 (en) 2015-10-20 2019-02-05 Zhejiang Hisun Pharmaceutical Co., Ltd. Crystal forms of bedaquiline fumarate and preparation methods therefor
CN108473428B (zh) * 2016-01-13 2021-07-23 上海嘉坦医药科技有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
EA201891644A1 (ru) * 2016-03-07 2019-04-30 Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк. Антибактериальные соединения и их применение
CN107243008B (zh) * 2017-04-13 2021-03-30 中国科学院广州生物医药与健康研究院 吡唑并[1,5-a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
EP3677687A4 (en) * 2017-09-01 2021-05-26 The Kitasato Institute NEW COMPOSITION WITH THERAPEUTIC EFFECT AGAINST INFECTIONS DUE TO THE MYCOBACTERIUM-AVIUM COMPLEX AND THE PROCESS FOR THEIR PRODUCTION
WO2020047596A1 (en) * 2018-09-04 2020-03-12 Monash University Antibacterial compounds and methods of use
KR20210113628A (ko) 2019-01-09 2021-09-16 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서의 조합물
CN115380029B (zh) * 2019-11-26 2025-06-17 南洋理工大学 用于治疗结核病的化合物
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
KR20230107275A (ko) 2020-11-12 2023-07-14 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물
CN117050006B (zh) * 2022-05-13 2026-02-13 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用
WO2023227123A1 (zh) * 2022-05-27 2023-11-30 广州嘉越医药科技有限公司 吡啶衍生物的用途
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
AU2023382389A1 (en) * 2022-11-15 2025-05-15 Eli Lilly And Company Ahr agonists
CN121941498A (zh) 2023-09-28 2026-04-28 詹森药业有限公司 用于治疗非结核分枝杆菌的atp合酶抑制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965572A (en) * 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399558A (en) * 1993-11-24 1995-03-21 Pathogenesis Corporation Isoflavonoid antibacterial compounds, compositions and use
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
JO2524B1 (en) * 2004-05-28 2010-03-17 جانسن فارمسيتكا ان في Use of substituted quinoline derivatives to treat drug-resistant microbial diseases
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965572A (en) * 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
李端.药理学 第2版.人民卫生出版社,1987,第406-409页.
李端.药理学 第2版.人民卫生出版社,1987,第406-409页. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102908347A (zh) * 2004-05-28 2013-02-06 詹森药业有限公司 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途
CN105330595A (zh) * 2014-07-14 2016-02-17 南京明德新药研发股份有限公司 吡啶衍生物及其作为抗分支杆菌的应用

Also Published As

Publication number Publication date
CY1110388T1 (el) 2015-04-29
JP2012229239A (ja) 2012-11-22
US20100168133A1 (en) 2010-07-01
IL179630A (en) 2011-05-31
JP2008500992A (ja) 2008-01-17
JP5675718B2 (ja) 2015-02-25
BRPI0510414A (pt) 2007-10-23
ES2306146T3 (es) 2008-11-01
TWI363625B (en) 2012-05-11
EA010651B1 (ru) 2008-10-30
DE602005005810D1 (de) 2008-05-15
KR101371653B1 (ko) 2014-03-07
DK1753427T3 (da) 2008-07-21
NO20066041L (no) 2007-02-27
IL179630A0 (en) 2007-07-04
WO2005117875A1 (en) 2005-12-15
AP2006003828A0 (en) 2006-12-31
CN1976704A (zh) 2007-06-06
JO2524B1 (en) 2010-03-17
NO338624B1 (no) 2016-09-19
UA90267C2 (ru) 2010-04-26
CN102908347A (zh) 2013-02-06
EP1753427A1 (en) 2007-02-21
TW200608974A (en) 2006-03-16
AU2005249231A1 (en) 2005-12-15
DE602005005810T2 (de) 2009-04-09
KR20130024969A (ko) 2013-03-08
ME01105B (me) 2013-03-20
ZA200609899B (en) 2009-01-28
SI1753427T1 (sl) 2008-10-31
NZ550840A (en) 2010-01-29
AP2037A (en) 2009-10-09
BRPI0510414B1 (pt) 2022-04-05
HK1106136A1 (en) 2008-03-07
MY140611A (en) 2009-12-31
US20070249667A1 (en) 2007-10-25
AR049127A1 (es) 2006-06-28
EA200602260A1 (ru) 2007-04-27
KR20070017393A (ko) 2007-02-09
RS50585B (sr) 2010-05-07
PT1753427E (pt) 2008-07-04
MXPA06013888A (es) 2007-01-26
EP1753427B1 (en) 2008-04-02
PA8635201A1 (es) 2006-05-16
PL1753427T3 (pl) 2008-09-30
CA2566544C (en) 2012-04-17
ATE390925T1 (de) 2008-04-15
CL2009001980A1 (es) 2010-04-16
AU2005249231B2 (en) 2010-11-11
CA2566544A1 (en) 2005-12-15
HRP20080307T3 (hr) 2008-07-31
JP5081617B2 (ja) 2012-11-28

Similar Documents

Publication Publication Date Title
KR101371653B1 (ko) 약물 내성 마이코박테리아 질환 치료를 위한 치환된 퀴놀린유도체의 용도
US20230059381A1 (en) Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
JP2014132023A (ja) 医薬組成物
WO2014080378A1 (en) Phenothiazine derivatives and their use against tuberculosis
WO2020245365A1 (en) Methods of treating cancer using prmt5 inhibitors
WO2010110428A1 (ja) 掻痒の予防及び／または治療剤
JP6025886B2 (ja) 慢性疼痛治療剤
HK1106136B (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
HK1177427A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
US7618986B2 (en) Method of treating latent tuberculosis
JP2009500440A (ja) 性欲障害治療用医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1106136

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1106136

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121205

CF01 Termination of patent right due to non-payment of annual fee